Revenio Group Corporation: SALES PERMIT FOR ICARE TA01 TONOMETER GRANTED IN CHINA


Revenio Group Corporation Stock Exchange Release, January 19, 2015 at 9:00 am


SALES PERMIT FOR ICARE TA01 TONOMETER GRANTED IN CHINA

Icare Finland Oy, which is part of the Renevio Group, has received a sales
permit for the company's TA01 tonometer in China. The company believes that the
sales permit will enable several hundred devices to be sold in China during
2015. In addition to the sales permit for the TA01 tonometer, Icare has applied
for a sales permit for its PRO and HOME tonometers in China, and the
applications have advanced to the stage of processing by the relevant
authorities.

The sales permit will enable sales work to be initiated with efficiently and the
distribution network to be expanded to cover China's key regions. Distributor
selections are currently underway. China is estimated to become an important
market for Icare in the future.

With the sales permit in China, Icare has a sales permit for its TA01 tonometer
in every key country, excluding Brazil. The application for a sales permit in
Brazil was submitted at the beginning of 2014.

Revenio Group Corporation
Olli-Pekka Salovaara
President & CEO

For additional information, please contact
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
http://www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
http://www.revenio.fi


The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy and Oscare Medical Oy, which specializes in osteoporosis screening,
monitoring and diagnosis. Revenio seeks vigorous growth in health technology,
both organically and through acquisitions and mergers.

The Revenio Group also includes other business operations, which comprise the
Technology and Services segment. As non-core businesses, the operations of this
segment have been classified as available-for-sale discontinued operations.

In 2013, the Revenio Group's net sales totaled MEUR 25.7, with its operating
margin standing at 21.7%. The Revenio Group Corporation is listed on NASDAQ OMX
Helsinki.

[HUG#1887889]